These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16293936)

  • 1. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation.
    Hayashi K; Wakino S; Homma K; Sugano N; Saruta T
    J Pharmacol Sci; 2005 Nov; 99(3):221-7. PubMed ID: 16293936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension.
    Hayashi K; Ozawa Y; Fujiwara K; Wakino S; Kumagai H; Saruta T
    Am J Nephrol; 2003; 23(4):229-44. PubMed ID: 12840599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-type Ca channel blockade as a determinant of kidney protection.
    Hayashi K; Homma K; Wakino S; Tokuyama H; Sugano N; Saruta T; Itoh H
    Keio J Med; 2010; 59(3):84-95. PubMed ID: 20881449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney.
    Ozawa Y; Hayashi K; Nagahama T; Fujiwara K; Saruta T
    Hypertension; 2001 Sep; 38(3):343-7. PubMed ID: 11566902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo.
    Honda M; Hayashi K; Matsuda H; Kubota E; Tokuyama H; Okubo K; Takamatsu I; Ozawa Y; Saruta T
    J Hypertens; 2001 Nov; 19(11):2031-7. PubMed ID: 11677369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal microcirculation and calcium channel subtypes.
    Homma K; Hayashi K; Yamaguchi S; Fujishima S; Hori S; Itoh H
    Curr Hypertens Rev; 2013 Aug; 9(3):182-6. PubMed ID: 24479750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular effects of calcium channel antagonists: new evidence.
    Richard S
    Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
    Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
    Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-type calcium channels in the regulation of afferent and efferent arterioles in rats.
    Feng MG; Li M; Navar LG
    Am J Physiol Renal Physiol; 2004 Feb; 286(2):F331-7. PubMed ID: 14583435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disparate effects of calcium antagonists on renal microcirculation.
    Hayashi K; Nagahama T; Oka K; Epstein M; Saruta T
    Hypertens Res; 1996 Mar; 19(1):31-6. PubMed ID: 8829821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment.
    Hayashi K; Kumagai H; Saruta T
    Am J Hypertens; 2003 Feb; 16(2):116-22. PubMed ID: 12559677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divergent natriuretic action of calcium channel antagonists in mongrel dogs: renal haemodynamics as a determinant of natriuresis.
    Honda M; Hayashi K; Matsuda H; Kubota E; Tokuyama H; Okubo K; Ozawa Y; Saruta T
    Clin Sci (Lond); 2001 Oct; 101(4):421-7. PubMed ID: 11566080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the renal action of pranidipine in the rat.
    Nagahama T; Hayashi K; Fujiwara K; Ozawa Y; Saruta T
    Arzneimittelforschung; 2000 Mar; 50(3):248-53. PubMed ID: 10758776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension.
    Tomino Y
    Curr Hypertens Rev; 2013 May; 9(2):108-14. PubMed ID: 23971692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats.
    Fujiwara K; Kanno Y; Hayashi K; Takenaka T; Saruta T
    Clin Exp Hypertens; 1998 Apr; 20(3):295-312. PubMed ID: 9605384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice.
    Abe M; Okada K; Soma M
    Curr Hypertens Rev; 2013 Aug; 9(3):202-9. PubMed ID: 24479749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide synthase inhibition activates L- and T-type Ca2+ channels in afferent and efferent arterioles.
    Feng MG; Navar LG
    Am J Physiol Renal Physiol; 2006 Apr; 290(4):F873-9. PubMed ID: 16263803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels.
    Tanaka H; Shigenobu K
    Cardiovasc Drug Rev; 2002; 20(1):81-92. PubMed ID: 12070536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
    Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
    Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.